Genmab — Maj 2026

[gdn55]

Købte en lille pæn sjat idag. Ligesom min kone ,som går meget op i tilbud på daglige varer gør. Jeg tror det var et af de bedste tilbud inden for aktier idag

[transalp]

Det giver mening EL, der findes større problemer end en dårlig dag for aktiekursen..

[w]

Orbis udnyttede udsalget og
er nu på 5,08%.

[ProinvestorNEWS]

Major Shareholder Announcement https://proinvestor.com/investornyt/1442512/major-shareholder-announcement

[E_L]

NICE issues Final Draft Guidance recommending that RYBREVANT▼ (amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/nice-guidance-rybrevant-nsclc-egfr-exon20-managed-access

[E_L]

Denecimig excels at reducing bleeds in hemophilia A patients: Study https://hemophilianewstoday.com/news/denecimig-excels-reducing-bleeds-hemophilia-a-patients/

[E_L]

Morgan Stanley lowered the firm's price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares. 8-5-26

[Raffles]

The study of GEN1057 has been terminated due to marginal anti-tumor activity not supporting further development, Ref ClinicalTrials (NCT06573294) 8/5 2026. This was one of the 100% owned Genmab antibodies. The study started 28/8 2024 and stopped after enrolling 23 patients.

[E_L]

Morningstart :- Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook

Rachel Elfman
May 11, 2026 - We maintain our fair value estimate of dkk 2.650

[E_L]

TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32

May 8 2026

[ProinvestorNEWS]

Genmab får gentaget "køb" hos Jefferies efter frustrationsreaktioner på forskningsnyt https://proinvestor.com/investornyt/1442956/genmab-far-gentaget-kob-hos-jefferies-efter-frustrationsreaktioner-pa-forskningsnyt

[E_L]

Stockwatch DK
@StockwatchDK
$GMAB
UBS reiterates its Buy rating on Genmab with a price target of DKK 2,600, saying the Q1 results were broadly in line with expectations. https://x.com/StockwatchDK/status/2053765010724159767

[E_L]

RYBREVANT▼ (amivantamab) with LAZCLUZE▼ (lazertinib) is accepted for use within NHS Scotland as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/rybrevant-amivantamab-with-lazcluze-lazertinib-is-accepted-for-use-within-nhs-scotland

[E_L]

from yesterday- Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares. 11-5-26

[Solsen]

Mærkelige spring i kursen. Skete for en uges tid siden også i US.

[Solsen]

Skete med åbning i US i et ellers surt marked.

[Raun]

Ja, det er sjovt som aktien springer engang imellem?..... Der skal også snart til at ske noget med kursen. Dette limbo halløj kan ikke blive ved - vi har ASCO om 3 ugers tid....

[Solsen]

Ligner pump and dump der startede med den mærkelige nedtur på regnskabet. Vi må se de kommende dage.

[ProinvestorNEWS]

Novo Nordisk er steget 30% på relativ kort tid - men hvad ligger bag stigningen? Hør også om DSV's AI-gevinster frem mod 2030, Genmab-kursfald, høje oliepriser samt meget mere i ugens afsnit af Investeringspodcasten. https://proinvestor.com/boards/132326

[peter12]

Interessant artikel om konkurrerende produkt til peto, hvor udvidelsen diskuteres https://seekingalpha.com/article/4904035-bicara-therapeutics-inc-bcax-presents-at-bank-of-america-global-healthcare-conference-2026